上海医药溴吡斯的明口服溶液获批生产

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of Pyridostigmine oral solution, which is used to treat myasthenia gravis [1] Company Summary - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Bromides of Pyridostigmine oral solution [1] - The drug was first launched in the United States in 1965, indicating a long history of use in the treatment of myasthenia gravis [1]